Literature DB >> 1752311

Relapse versus reinfection with Clostridium difficile.

G L O'Neill1, M H Beaman, T V Riley.   

Abstract

Relapse of Clostridium difficile-associated diarrhoea occurs in 15-20% of patients; however, whether relapse is due to an endogenous source of the organism or reinfection from the environment remains unclear. Restriction enzyme analysis (REA) of chromosomal DNA was used to type multiple isolates from ten patients who had experienced apparent relapses. More than half the relapses were due to infection with a new strain of C. difficile. The remaining patients were infected with the same strain, but whether this strain was acquired from the environment or from endogenous sources could not be determined. Relapses with a different strain of C. difficile could occur if an individual harboured more than one strain in their gastrointestinal tract. To investigate this possibility ten other patients were assessed for carriage of multiple strains. Ten colonies from a primary culture plate from each patient were typed by REA and tested for their ability to produce cytotoxin. All isolates from the same patient were identical by both methods, indicating that multiple carriage of strains may be a rare event.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752311      PMCID: PMC2272080          DOI: 10.1017/s0950268800049323

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  23 in total

1.  Application of whole-cell DNA restriction endonuclease profiles to the epidemiology of Clostridium difficile-induced diarrhea.

Authors:  E J Kuijper; J H Oudbier; W N Stuifbergen; A Jansz; H C Zanen
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

2.  Epidemiology and prevention of Clostridium difficile infections in a leukemia unit.

Authors:  M Delmée; B Vandercam; V Avesani; J L Michaux
Journal:  Eur J Clin Microbiol       Date:  1987-12       Impact factor: 3.267

3.  Is Clostridium difficile endemic in chronic-care facilities?

Authors:  B S Bender; R Bennett; B E Laughon; W B Greenough; C Gaydos; S D Sears; M S Forman; J G Bartlett
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

4.  Isolation of Clostridium difficile from patients and the environment of hospital wards.

Authors:  H Malamou-Ladas; S O'Farrell; J Q Nash; S Tabaqchali
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

5.  Typing of Clostridium difficile causing diarrhoea in an orthopaedic ward.

Authors:  I McKay; J E Coia; I R Poxton
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

6.  Contamination and crossinfection with Clostridium difficile in an intensive care unit.

Authors:  B A Walters; R Stafford; R K Roberts; E Seneviratne
Journal:  Aust N Z J Med       Date:  1982-06

7.  Concomitance of cytotoxigenic and non-cytotoxigenic Clostridium difficile in stool specimens.

Authors:  S P Borriello; P Honour
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

8.  Clostridium difficile in general practice and community health.

Authors:  T V Riley; V Wymer; V W Bamford; R A Bowman
Journal:  J Hyg (Lond)       Date:  1986-02

9.  Latex particle agglutination for detecting and identifying Clostridium difficile.

Authors:  R A Bowman; S A Arrow; T V Riley
Journal:  J Clin Pathol       Date:  1986-02       Impact factor: 3.411

10.  Is pseudomembranous colitis infectious?

Authors:  C Greenfield; A Burroughs; M Szawathowski; N Bass; P Noone; R Pounder
Journal:  Lancet       Date:  1981-02-14       Impact factor: 79.321

View more
  32 in total

1.  Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.

Authors:  F Barbut; A Richard; K Hamadi; V Chomette; B Burghoffer; J C Petit
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Clostridium difficile mixed infection and reinfection.

Authors:  David W Eyre; A Sarah Walker; David Griffiths; Mark H Wilcox; David H Wyllie; Kate E Dingle; Derrick W Crook; Tim E A Peto
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

3.  Relapse versus reinfection: surveillance of Clostridium difficile infection.

Authors:  Mini Kamboj; Perminder Khosa; Anna Kaltsas; N Esther Babady; Crystal Son; Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

Review 4.  Antibiotic-associated diarrhoea. A costly problem.

Authors:  T V Riley
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

5.  Efficacy of LFF571 in a hamster model of Clostridium difficile infection.

Authors:  Anna Trzasko; Jennifer A Leeds; Jens Praestgaard; Matthew J Lamarche; David McKenney
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

6.  Clostridium difficile: a pathogen of the nineties.

Authors:  T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

7.  Role of Coinfecting Strains in Recurrent Clostridium difficile Infection.

Authors:  Janet Sun; Tracy Mc Millen; N Esther Babady; Mini Kamboj
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

8.  Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea.

Authors:  Yajarayma Tang-Feldman; Susan Mayo; Joseph Silva; Stuart H Cohen
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  A molecular characterization of Clostridium difficile isolates from humans, animals and their environments.

Authors:  G O'Neill; J E Adams; R A Bowman; T V Riley
Journal:  Epidemiol Infect       Date:  1993-10       Impact factor: 2.451

10.  Investigation of an outbreak of Clostridium difficile infection in a general hospital by numerical analysis of protein patterns by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  M Costas; B Holmes; S L On; M Ganner; M C Kelly; S K Nath
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.